Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Treatment paradigms in lung NET have conventionally relied on therapies such as chemotherapy, radiotherapy and somatostatin analogs (SSA) although evidence from randomized clinical trials remains limited.
Background: In the CLARINET trial, lanreotide (LAN) 120 mg resulted in a 53% reduction in the risk of death or disease progression, compared with placebo, in GI-NET patients. Several studies have identified diabetic patients (pts) as having increased risk for the development of cancer and have associated metformin (MET) treatment with a decrease of cancer risk.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
